New stem cell therapy to improve fight against leukemia

November 29, 2018, University of Zurich
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia

Stem cell transplantation is effective against leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue—often with fatal consequences. Researchers at the University of Zurich have now identified a molecule that plays a key role in this process. Blocking this molecule could significantly improve the outcome of patients receiving stem cell transplants.

Stem cell therapy offers people suffering from leukemia or the chance of full recovery. This requires eliminating the affected cells using chemo or radiation therapy and then replacing them with the from a healthy . The donor cells produce new blood cells and attack the other in the patient's body, preventing a relapse.

Dangerous response

However, this form of therapy is not without its risks. In 30 percent to 60 percent of cases, the donor cells also attack the recipients' healthy tissue—the liver, intestine and skin, in particular. In about half of affected patients, such responses even have fatal consequences. This is why doctors try to suppress this type of with drugs that inhibit the immune system. But this procedure has a drawback: Since it also diminishes the donor cells' anti-cancer effect on cancer cells in the rest of the body. "There is an urgent need to understand how to reduce graft-versus-host responses without losing the anti-cancer effects of the transferred cells," says Burkhard Becher, professor at the Institute of Experimental Immunology of UZH.

Cytokines responsible for attack

His team, in collaboration with the UniversityHospital Zurich and the University Medical Center at the University of Freiburg in Germany, has now demonstrated that the production of a cytokine called GM-CSF is a decisive factor in graft-versus-host pathology. This cytokine, produced by a specific group of white blood cells, helps fight infections in healthy people.

The researchers used a to show that transplanted cells produce large amounts of GM-CSF during graft-versus-host responses. If the mice were given donor cells that were unable to produce GM-CSF, however, they were protected against the lethal response. "Targeting this cytokine is therefore a very precise and specific form of immunosuppression, designed to stop the tissue damage caused by graft-versus-host responses," says Becher.

The immunologists were initially concerned that neutralizing GM-CSF would also diminish the donor ' anti-cancer effect; however, further tests showed that this wasn't the case. "This finding really surprised us," says Sònia Tugues, one of the study's first authors, "since both types of immune response were previously thought to be mediated through the same mechanisms." The researchers thus believe that they have discovered a method that will allow them to separate the desired from the undesired processes in the donor cell.

Translating the results from mice to humans

Next, the researchers checked whether GM-CSF plays the same key role in humans as it does for mice. They did this by analyzing patient samples that had been affected by a graft-versus-host response. It emerged that these samples also had elevated levels of the —the stronger a patient's graft-versus-host response, the higher the amount of CM-CSF measured.

The researchers now want to run a clinical trial to test whether the blocking of GM-CSF can prevent the graft-versus-host response after . To this end, the immunologists have already contacted a company that has developed a monoclonal antibody against GM-CSF. "If we can stop the graft-versus-host response while preserving the anti-cancer effect, this procedure can be employed much more successfully and with fewer risks to the patient," says Becher. "This therapeutic strategy holds particular promise for patients with the poorest prognosis and highest risk of fatality."

The study is published in Science Translational Medicine.

Explore further: Experimental arthritis drug prevents stem cell transplant complication

More information: S. Tugues el al., "Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells," Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aat8410

Related Stories

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

Researchers successfully prevent graft-versus-host disease

April 18, 2017
Through experimental work, an international team of researchers led by City of Hope's Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation, believe they may have found a way to prevent graft-versus-host ...

Depletion of naive T cells from stem cell grafts limits chronic graft-versus host disease

June 8, 2015
Stem cell transplantation is used to treat hematologic malignancies, such as leukemia. Patients that receive donor cells are at risk of developing graft-versus host disease (GVHD). This potentially fatal complication results ...

Using light to fight GVHD

August 31, 2018
Extracorporeal photopheresis (ECP) is used to treat chronic graft-versus-host disease (cGVHD)—a complication of bone marrow or stem cell transplant that occurs when donor cells attack the recipient. How ECP works is unclear, ...

Using software, researchers predict tumor markers that could be immune targets

December 11, 2017
University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients ...

Researchers identify new target to reduce risk of GVHD

February 5, 2018
Stem cell transplants can cure patients with high-risk leukemia or lymphoma. Graft-versus-host disease (GVHD) is a potentially life-threatening side effect that occurs when the donor's immune cells attack the recipient's ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

HIV vaccine protects non-human primates from infection

December 14, 2018
For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human ...

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

The 'greying' of T cells: Scientists pinpoint metabolic pathway behind age-related immunity loss

December 13, 2018
The elderly suffer more serious complications from infections and benefit less from vaccination than the general population. Scientists have long known that a weakened immune system is to blame but the exact mechanisms behind ...

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.